A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa

Trial Profile

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Allantoin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Registrational; Therapeutic Use
  • Acronyms ESSENCE
  • Sponsors Amicus Therapeutics; Scioderm
  • Most Recent Events

    • 13 Sep 2017 Primary endpoint of proportion of patients experiencing complete closure of their target wound has not been met, according to an Amicus Therapeutics media release.
    • 13 Sep 2017 Primary endpoint of time to complete target wound closure has not been met, according to an Amicus Therapeutics media release.
    • 13 Sep 2017 Results published in an Amicus Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top